Prostate CancerNCT07631858
Perspectives About Online Information
A study testing Post (video) about prostate cancer, Post (text post) about prostate cancer and Survey in people with Prostate Cancer, run by NYU Langone Health at 1 site in United States.
Trial summary
The purpose of this research study is to understand the perspectives of U.S. adults on online information about prostate cancer. Study participants will receive different online information about prostate cancer to view such as a video post or text post, and complete a one-time online survey that will take… Read more about this study
- Who is it for?
- Ages 40 years and olderHealthy volunteers can take part
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Post (video) about prostate cancer, Post (text post) about prostate cancer and Survey
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,200 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2026to 31 Jan 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- U.S. adult age 40+ who identifies as Black and/or Hispanic
- Enrolled in Dynata online survey panel
- Willing and able to participate in the research study.
Who cannot join
- Individuals up to age 39
- Individuals living outside the U.S.
- Individuals who are not Black and/or Hispanic
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The purpose of this research study is to understand the perspectives of U.S. adults on online information about prostate cancer. Study participants will receive different online information about prostate cancer to view such as a video post or text post, and complete a one-time online survey that will take approximately 10 minutes.
- Conditions
- Prostate Cancer
- Being tested
- Post (video) about prostate cancer, Post (text post) about prostate cancer, Survey
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Post (video) about prostate cancerOther
Participants will review a post about prostate cancer.
Post (text post) about prostate cancerOther
Participants will review a post about prostate cancer.
SurveyOther
The survey will include questions about demographics and internet use. It may also provide participants with resources about online information.
| Study group | Role | What they receive |
|---|---|---|
| Prostate Cancer Post with Video | Experimental | Participants will receive a survey and be asked their perspective after reviewing a prostate cancer post with video Receives: Other: Post (video) about prostate cancer; Other: Survey |
| Prostate Cancer Post without Video | Experimental | Participants will receive a survey and be asked their perspective after reviewing a prostate cancer post without video. Receives: Other: Post (text post) about prostate cancer; Other: Survey |
What is being measured
The primary outcome is the main question the study is designed to answer.
Trust in the post, as measured by a 4-point Likert scale
A single question is asked of "How much do you trust the information in the post?" Participants used a 4-point Likert scale from 1 (trust the information completely) to 4 (Did not trust the information). Scores range from 1-4, with higher scores indicating less trust.
Measured: Post-intervention (~5 minutes)
Secondary outcomes (2)
Short-form Positive and Negative Affect Schedule (PANAS) Positive Score
The Short-form Positive and Negative Affect Schedule (PANAS-SF) is a brief, 10-item psychometric tool used to assess two distinct emotional dimensions: Positive Affect (e.g., active, inspired) and Negative Affect (e.g., upset, afraid). Respondents rate each of the 10 adjectives on a 5-point Likert scale. Scores can range from 10 - 50, with higher scores representing higher levels of positive affect.
Measured: Post-intervention (~5 minutes)
Short-form Positive and Negative Affect Schedule (PANAS) Negative Score
The Short-form Positive and Negative Affect Schedule (PANAS-SF) is a brief, 10-item psychometric tool used to assess two distinct emotional dimensions: Positive Affect (e.g., active, inspired) and Negative Affect (e.g., upset, afraid). Respondents rate each of the 10 adjectives on a 5-point Likert scale. Scores can range from 10 - 50, with lower scores representing lower levels of negative affect.
Measured: Post-intervention (~5 minutes)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start1 Jul 2026 (estimated)
- Primary completion31 Jan 2028 (estimated)
- Study completion31 Jan 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 3,200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Stacy Loeb, MD, MSc, PhD, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07631858
- Sponsor's protocol ID
- 25-01456
- Other IDs
- 1R01CA278997
- Status last verified
- Jun 2026
- First submitted
- 2 Jun 2026
- Last updated
- 8 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: stacy.loeb@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Perspectives About Online Information
- ClinicalTrials.gov ID
- NCT07631858
- Acronym / sponsor ID
- 25-01456
- Conditions
- Prostate Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 3,200 participants (estimated)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 1 Jul 2026 (estimated)
- Primary completion
- 31 Jan 2028 (estimated)
- Study completion
- 31 Jan 2028 (estimated)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this research study is to understand the perspectives of U.S. adults on online information about prostate cancer. Study participants will receive different online information about prostate cancer to view such as a video post or text post, and complete a one-time online survey that will take approximately 10 minutes.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Prostate Cancer Post with Video | Experimental | Other: Post (video) about prostate cancer, Other: SurveyParticipants will receive a survey and be asked their perspective after reviewing a prostate cancer post with video |
| Prostate Cancer Post without Video | Experimental | Other: Post (text post) about prostate cancer, Other: SurveyParticipants will receive a survey and be asked their perspective after reviewing a prostate cancer post without video. |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- U.S. adult age 40+ who identifies as Black and/or Hispanic
- Enrolled in Dynata online survey panel
- Willing and able to participate in the research study.
Key exclusion criteria (3 listed)
- Individuals up to age 39
- Individuals living outside the U.S.
- Individuals who are not Black and/or Hispanic
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Post (video) about prostate cancerParticipants will review a post about prostate cancer. | Other | Prostate Cancer Post with Video |
| Post (text post) about prostate cancerParticipants will review a post about prostate cancer. | Other | Prostate Cancer Post without Video |
| SurveyThe survey will include questions about demographics and internet use. It may also provide participants with resources about online information. | Other | Prostate Cancer Post with Video, Prostate Cancer Post without Video |
Primary outcome
Trust in the post, as measured by a 4-point Likert scale
Time frame: Post-intervention (~5 minutes)
A single question is asked of "How much do you trust the information in the post?" Participants used a 4-point Likert scale from 1 (trust the information completely) to 4 (Did not trust the information). Scores range from 1-4, with higher scores indicating less trust.
2 secondary outcomes
Short-form Positive and Negative Affect Schedule (PANAS) Positive Score
Time frame: Post-intervention (~5 minutes)
Short-form Positive and Negative Affect Schedule (PANAS) Negative Score
Time frame: Post-intervention (~5 minutes)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2026.
- Individual participant dataSharing planned: Yes. The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: stacy.loeb@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Related trials for Prostate Cancer
Enrolling by invitation
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
Adenocarcinoma, Prostate Neoplasms
RecruitingObservational study
Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
Prostatic Neoplasms, Prostate Cancer
RecruitingObservational study
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
Prostate Cancer
RecruitingObservational study
Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations
Prostate Cancer
RecruitingPhase 1/2
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
Cancer Of Prostate, Prostate Neoplasms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Stacy Loeb, MD, MSc, PhD principal investigator
NYU Langone Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Post (video) about prostate cancer, Post (text post) about prostate cancer and Survey in people with Prostate Cancer, run by NYU Langone Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 8 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Stacy Loeb, MD, MSc, PhD (646-825-6300, Stacy.loeb@nyulangone.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Trust in the post, as measured by a 4-point Likert scale (time frame: Post-intervention (~5 minutes)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2026; AzTrials last refreshed its copy on 30 Oct 2026.